Greg Wright Email

Director, Clinical Operations . Albireo Pharma

Current Roles

Employees:
125
Revenue:
$24.2M
About
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Albireo Pharma Address
53 State Street
Boston, MA
United States
Albireo Pharma Email

Past Companies

Albireo Pharma, Inc.Director, Clinical Operations
Albireo Pharma, Inc.Associate Director Clinical Operations
Karyopharm Therapeutics Inc.Senior Clinical Project Manager, NDA and Inspection Readiness Lead

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.